ClinicalTrials.gg
RecruitingNCT07409428Updated Nov 10, 2026

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

A Phase 3 interventional study of HMPL-760 and HMPL-760 Placebo in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, sponsored by Hutchmed. Recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hutchmed · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 10, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.

Planned enrollment
51st of 277
240 · median 59
Started
2026
with 29 others
Phase 3
57 of 306
18 open now
Primary completion
2028-04
later than 120 of 164 live
Registered
276th of 306
by date

Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 51st largest by planned enrollment of the 277 interventional ones that give a count, is one of 30 that started in 2026, is one of 57 in phase 3, reaches primary completion later than 120 of the 164 other live ones, and was the 276th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:

137 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, or all of them as a file.
02

Study summary

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Read the detailed description

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Keywords

  • HMPL-760
  • R-GemOx (rituximab, gemcitabine, and oxaliplatin)
  • R/R DLBCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally ;
  7. Expected survival is more than 12 weeks;

Exclusion criteria

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with (HIV), virus (HBV), or virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. active infection;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    The experimental group

    Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

    Drug: HMPL-760 · Drug: R-GemOx

  • Placebo comparator
    The control group

    Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

    Drug: HMPL-760 Placebo · Drug: R-GemOx

Interventions

  • Patients will receive HMPL-760 once daily (QD) orally.

  • DrugHMPL-760 Placebo

    Patients will receive HMPL-760 placebo once daily (QD) orally.

  • DrugR-GemOx

    R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

    Also known as: Rituximab Injection, Gemcitabine Hydrochloride for Injection, Oxaliplatin Injection

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately two years

  2. End of treatment (EOT)

    Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

    Time frame: Up to approximately two years

  3. Systemic antitumor therapy

    Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

    Time frame: Up to approximately two years

  4. Overall survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately two years

  5. systematic anti-tumor therapy

    OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

    Time frame: Up to approximately two years

  6. Premature withdrawal from study treatment

    OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

    Time frame: Up to approximately two years

Secondary outcomes

  1. Independent review committee (IRC)-assessed PFS

    Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: Up to approximately two years

  2. IRC- and investigator-assessed objective response rate (ORR)

    Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

    Time frame: Up to approximately two years

  3. IRC- and investigator-assessed complete response rate (CRR)

    Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

    Time frame: Up to approximately two years

  4. IRC- and investigator-assessed duration of response (DoR)

    For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

    Time frame: Up to approximately two years

  5. IRC- and investigator-assessed clinical benefit rate (CBR)

    Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

    Time frame: Up to approximately two years

  6. IRC- and investigator-assessed time to response (TTR)

    Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

    Time frame: Up to approximately two years

  7. Safety Endpoints

    * Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0). * Changes in laboratory tests, vital signs, 12-lead ECG, etc.

    Time frame: Up to approximately two years

  8. PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx

    including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose \[trough concentrations (Ctrough)\] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

    Time frame: At the end of Cycle 4 (each cycle is 21 days)]

Other outcomes

  1. Biomarker assessment

    Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

    Time frame: Up to approximately two years

  2. To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients

    Human metabolites of HMPL-760 when co-administered with R-GemOx

    Time frame: Up to approximately two years

  3. Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760

    maximum concentration in steady-state (Cmax,ss)

    Time frame: Up to approximately two years

  4. Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760

    time to maximum concentration in steady-state (Tmax,ss)

    Time frame: Up to approximately two years

  5. Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760

    Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

    Time frame: Up to approximately two years

  6. Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760

    The rate at which the drug is eliminated from the body (CL/F) (if applicable )

    Time frame: Up to approximately two years

  7. Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760

    The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

    Time frame: Up to approximately two years

07

Study locations

48 of 51 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 25 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 13, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • The First Affiliated Hospital of Chongqing Medical University · Chongqing, ChinaNot yet recruiting→Recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
  • The First Affiliated Hospital, Zhejiang University · Hangzhou, ChinaNot yet recruiting→Recruiting
  • Qilu Hospital of Shandong University · Jinan, ChinaNot yet recruiting→Recruiting
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, ChinaNot yet recruiting→Recruiting
  • Shengjing Hospital of China Medical University · Shenyang, ChinaNot yet recruiting→Recruiting
  • Shenzhen people's hospital · Shenzhen, ChinaNot yet recruiting→Recruiting
  • People's Hospital of Xinjiang Uygur Autonomous Region · Ürümqi, ChinaNot yet recruiting→Recruiting
  • The First Affiliated Hospital of WMU · Wenzhou, ChinaNot yet recruiting→Recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal) · Xi'an, ChinaNot yet recruiting→Recruiting
  • The Affiliated Hospital of Xuzhou Medical University · Xuzhou, ChinaNot yet recruiting→Recruiting
Show site
  • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine · Shanghai, China
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • The First Affiliated Hospital of Chongqing Medical University · Chongqing, ChinaNot yet recruiting→Recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
    • The First Affiliated Hospital, Zhejiang University · Hangzhou, ChinaNot yet recruiting→Recruiting
    • Qilu Hospital of Shandong University · Jinan, ChinaNot yet recruiting→Recruiting
    • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, ChinaNot yet recruiting→Recruiting
    • Shengjing Hospital of China Medical University · Shenyang, ChinaNot yet recruiting→Recruiting
    • Shenzhen people's hospital · Shenzhen, ChinaNot yet recruiting→Recruiting
    • People's Hospital of Xinjiang Uygur Autonomous Region · Ürümqi, ChinaNot yet recruiting→Recruiting
    • The First Affiliated Hospital of WMU · Wenzhou, ChinaNot yet recruiting→Recruiting
    • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal) · Xi'an, ChinaNot yet recruiting→Recruiting
    • The Affiliated Hospital of Xuzhou Medical University · Xuzhou, ChinaNot yet recruiting→Recruiting
    Show site
    • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine · Shanghai, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409428
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Mar 20, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Dongmei Chen, CPL
Contact
dongmeic@hutch-med.com
86-21-20671794
Weili Zhao
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor HMPL-760

Start the discussion